What Happened?

Shares of medical tech company Masimo (NASDAQ: MASI) jumped 11.6% in the afternoon session after the company reported impressive fourth-quarter 2024 results, which beat analysts' revenue and EPS expectations. Sales grew 9% year on year, fueled by broad based demand. In addition, its full-year EPS guidance outperformed Wall Street's estimates by a wide margin. Zooming out, we think this was a solid quarter.

Is now the time to buy Masimo? Access our full analysis report here, it’s free.

What The Market Is Telling Us

Masimo’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. Moves this big are rare for Masimo and indicate this news significantly impacted the market’s perception of the business.

Masimo is up 11.6% since the beginning of the year, and at $188.06 per share, has set a new 52-week high. Investors who bought $1,000 worth of Masimo’s shares 5 years ago would now be looking at an investment worth $1,123.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.